BRIEF-Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln
February 21, 2017 at 07:30 AM EST
* Sarepta Therapeutics agrees to sale of priority review voucher for $125m
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.